XNASSRTS
Market cap117mUSD
Dec 24, Last price
7.14USD
1D
3.93%
1Q
28.88%
Jan 2017
36.00%
IPO
12.97%
Name
Sensus Healthcare Inc
Chart & Performance
Profile
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 24,405 -45.20% | 44,532 64.68% | 27,042 182.37% | |||||||
Cost of revenue | 24,787 | 29,701 | 22,922 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (382) | 14,831 | 4,120 | |||||||
NOPBT Margin | 33.30% | 15.24% | ||||||||
Operating Taxes | 167 | 3,746 | (613) | |||||||
Tax Rate | 25.26% | |||||||||
NOPAT | (549) | 11,085 | 4,733 | |||||||
Net income | 485 -98.00% | 24,244 488.59% | 4,119 -187.35% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (27) | (2,268) | (15) | |||||||
BB yield | 0.07% | 1.84% | 0.01% | |||||||
Debt | ||||||||||
Debt current | 374 | 190 | 225 | |||||||
Long-term debt | 1,379 | 1,850 | 174 | |||||||
Deferred revenue | 60 | 139 | 262 | |||||||
Other long-term liabilities | (12) | |||||||||
Net debt | (21,395) | (23,480) | (14,120) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (2,145) | (1,412) | (286) | |||||||
CAPEX | (229) | (159) | (128) | |||||||
Cash from investing activities | (187) | 14,841 | 129 | |||||||
Cash from financing activities | (40) | (2,428) | (231) | |||||||
FCF | (2,445) | 926 | 1,114 | |||||||
Balance | ||||||||||
Cash | 23,148 | 25,520 | 14,519 | |||||||
Long term investments | ||||||||||
Excess cash | 21,928 | 23,293 | 13,167 | |||||||
Stockholders' equity | 6,956 | 6,471 | (17,775) | |||||||
Invested Capital | 42,916 | 41,855 | 44,277 | |||||||
ROIC | 25.74% | 10.53% | ||||||||
ROCE | 30.68% | 15.55% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 16,266 | 16,618 | 16,503 | |||||||
Price | 2.36 -68.19% | 7.42 2.77% | 7.22 87.05% | |||||||
Market cap | 38,388 -68.87% | 123,307 3.49% | 119,153 87.83% | |||||||
EV | 16,993 | 99,827 | 105,033 | |||||||
EBITDA | 79 | 15,146 | 4,733 | |||||||
EV/EBITDA | 215.10 | 6.59 | 22.19 | |||||||
Interest | 2 | 1,000 | ||||||||
Interest/NOPBT | 0.01% | 0.02% |